TY - JOUR
T1 - Screening for inflammatory markers identifies IL18-Rα as a potential link between exenatide and its anti-inflammatory effect. New results from the Combat-JUDO randomized controlled trial
AU - Stenlid, Rasmus
AU - Cerenius, Sara Y
AU - Manell, Hannes
AU - Küçükemre Aydin, Banu
AU - Mörwald, Katharina
AU - Gomahr, Julian
AU - Höghammar Mitkas, Marina
AU - Eriksson, Ida
AU - Ciba, Iris
AU - Geiersberger, Sabine
AU - Thivel, David
AU - Weghuber, Daniel
AU - Bergsten, Peter
AU - Forslund, Anders
N1 - Mörwald, Gomahr, Weghuber: Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria; Obesity Research Unit, Paracelsus Medial University, Salzburg, Austria
PY - 2023/10/26
Y1 - 2023/10/26
N2 - INTRODUCTION: Obesity is associated with chronic inflammation. Chronic inflammation has also been linked to insulin resistance and type 2 diabetes, non-alcoholic fatty liver disease and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor analogs (GLP-1RA) are clinically used to treat obesity, with known anti-inflammatory properties. How the GLP-1RA exenatide effects inflammation in adolescents with obesity is not fully investigated.METHODS: 44 patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months. Plasma samples were collected at baseline and at the end of the study, and 90 inflammatory proteins were measured.RESULTS: Following treatment with exenatide, 15 out of the 90 proteins were decreased, and one was increased. However, after adjustment for multiple testing, only IL18-Rα was significantly lowered following treatment.CONCLUSIONS: Weekly injections with 2 mg of exenatide lowers circulating IL18-Rα in adolescents with obesity, which may be a potential link between exenatide and its anti-inflammatory effect in vivo. This contributes to exenatide's pharmaceutical potential as a treatment for obesity beyond weight control and glucose tolerance, and should be further studied mechanistically.
AB - INTRODUCTION: Obesity is associated with chronic inflammation. Chronic inflammation has also been linked to insulin resistance and type 2 diabetes, non-alcoholic fatty liver disease and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor analogs (GLP-1RA) are clinically used to treat obesity, with known anti-inflammatory properties. How the GLP-1RA exenatide effects inflammation in adolescents with obesity is not fully investigated.METHODS: 44 patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months. Plasma samples were collected at baseline and at the end of the study, and 90 inflammatory proteins were measured.RESULTS: Following treatment with exenatide, 15 out of the 90 proteins were decreased, and one was increased. However, after adjustment for multiple testing, only IL18-Rα was significantly lowered following treatment.CONCLUSIONS: Weekly injections with 2 mg of exenatide lowers circulating IL18-Rα in adolescents with obesity, which may be a potential link between exenatide and its anti-inflammatory effect in vivo. This contributes to exenatide's pharmaceutical potential as a treatment for obesity beyond weight control and glucose tolerance, and should be further studied mechanistically.
KW - Glp-1
KW - Il-18
KW - IL-18R alpha
KW - Inflammation
KW - Obesity
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001097738100001&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1159/000534725
DO - 10.1159/000534725
M3 - Original Article
C2 - 37883939
SN - 0250-6807
JO - ANNALS OF NUTRITION AND METABOLISM
JF - ANNALS OF NUTRITION AND METABOLISM
ER -